Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Mononuclear Cells in Traumatic Brain Injury
NCT02028104Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Jan 2010
- Primary completion
- Apr 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in traumatic brain injury (TBI), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Change in clinical symptoms of traumatic brain injury at 6 months. Planned start Jan 2010; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02028104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028104.